Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Hematology & Oncology

Topics

Medicine

Pathology

Internal Medicine

Hematology

Surgery

Show all topics

DOI

10.1186/s13045-017-0417-z

License

CC-BY

Other Formats

PDF